Pembrolizumab and lenvatinib for recurrent endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for women whose endometrial cancer has returned after initial treatment with immunotherapy. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have endometrial cancer that has come back after treatment, and it is one of these types: serous, endometrioid, carcinosarcoma, or clear cell.
- Your cancer is mismatch repair proficient (meaning it has normal repair mechanisms).
- Your cancer grew or came back while you were on or after finishing your first maintenance immunotherapy treatment.
- You are 18 years or older and have a performance status of 0 to 3 (meaning you are able to do daily activities).
- You have at least one tumor that can be measured on scans.
- Your blood counts and kidney and liver function are within the required levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two oral medications (letrozole and abemaciclib) after standard chemotherapy can help keep advanced or recurrent endometrial cancer from coming back. It is for people whose cancer is estrogen receptor-positive and has certain favorable genetic features.
This study tests a combination of two drugs (lenvatinib and pembrolizumab) plus focused radiation to the pelvis for a specific type of endometrial cancer that has returned or cannot be surgically removed. The goal is to see if this treatment is safe and effective for tumors that are pMMR and limited to the pelvic area.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
This study tests whether adding a repurposed drug to the standard combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) can help treat advanced or recurrent endometrial cancer. It is for people whose cancer has returned or progressed after platinum chemotherapy and who are not suitable for curative surgery or radiation.
This study tests whether adding another drug to the standard combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) can help treat advanced or recurrent endometrial cancer that has already progressed after platinum-based chemotherapy. If you qualify, you may have access to a new treatment option while helping doctors learn what works best.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
Hear when a new Recurrent Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.